Description:
This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and
safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive
locally advanced or metastatic urothelial carcinoma who have received prior
platinum-containing chemotherapy.
The primary objective is to demonstrate the superiority of rogaratinib over chemotherapy in
terms of objective response rate (before: overall survivial) of urothelial carcinoma patients
with FGFR positive tumors.
At randomization, patients will have locally advanced or metastatic urothelial carcinoma and
have received at least one prior platinum-containing chemotherapy regimen. Only patients with
FGFR1 or 3 positive tumors can be randomized into the study. Archival tumor tissue is
adequate for testing of FGFR1 and 3 mRNA expressions, which will be determined centrally
using an RNA in situ hybridization (RNA-ISH) test. Approximately 42 % of UC patients with
locally advanced or metastatic UC are identified as FGFR-positive by the RNA-ISH cut-off
applied.
Title
- Brief Title: Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma
- Official Title: A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy
Clinical Trial IDs
- ORG STUDY ID:
17403
- SECONDARY ID:
2016-004340-11
- NCT ID:
NCT03410693
Conditions
- Carcinoma, Transitional Cell
Interventions
Drug | Synonyms | Arms |
---|
Rogaratinib (BAY1163877) | | Rogaratinib |
Chemotherapy | | Chemotherapy |
Purpose
This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and
safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive
locally advanced or metastatic urothelial carcinoma who have received prior
platinum-containing chemotherapy.
The primary objective is to demonstrate the superiority of rogaratinib over chemotherapy in
terms of objective response rate (before: overall survivial) of urothelial carcinoma patients
with FGFR positive tumors.
At randomization, patients will have locally advanced or metastatic urothelial carcinoma and
have received at least one prior platinum-containing chemotherapy regimen. Only patients with
FGFR1 or 3 positive tumors can be randomized into the study. Archival tumor tissue is
adequate for testing of FGFR1 and 3 mRNA expressions, which will be determined centrally
using an RNA in situ hybridization (RNA-ISH) test. Approximately 42 % of UC patients with
locally advanced or metastatic UC are identified as FGFR-positive by the RNA-ISH cut-off
applied.
Trial Arms
Name | Type | Description | Interventions |
---|
Rogaratinib | Experimental | Rogaratinib treatment study arm, comprising
Pre-treatment period, including FGFR testing and screening,
Treatment period, and
Follow-up period, including active follow-up and long-term follow-up. Patients will be considered "on study" during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered "off study". | |
Chemotherapy | Active Comparator | Chemotherapy treatment study arm, comprising
Pre-treatment period, including FGFR testing and screening,
Treatment period, and
Follow-up period, including active follow-up and long-term follow-up. Patients will be considered "on study" during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered "off study". | |
Eligibility Criteria
Inclusion Criteria:
- Existence of archival or fresh biopsy for FGFR testing. Mandatory FGFR testing of
patients will be performed prior to start of screening. The timing of the FGFR test is
at the discretion of the investigator. Investigators should ensure all patients will
be eligible in terms of disease status and lines of treatment.
- Documented urothelial carcinoma (transitional cell carcinoma) including urinary
bladder, renal pelvis, ureters, urethra meeting all of the following criteria
- Histologically confirmed (Patients with mixed histologies are required to have a
dominant transitional cell pattern.)
- Locally advanced (T4, any N; or any T, N 2-3) or metastatic disease (any T, any N
and M1). Locally advanced bladder cancer must be unresectable i.e. invading the
pelvic or abdominal wall (stage T4b) or presenting with bulky nodal disease
(N2-3).
- ECOG (Eastern Cooperative Oncology Group) Performance Status of 0 or 1
- Disease progression during or following treatment with at least one
platinum-containing regimen (patients should have been treated for at least 2 cycles).
In patients who received prior adjuvant/ neoadjuvant platinum-containing chemotherapy,
progression had to occur within 12 months of treatment.
- High FGFR1 or 3 mRNA expression levels in archival or fresh tumor biopsy specimen
quantified as outlined in the lab manual
- At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors
(RECIST v.1.1) in contrast enhanced (unless contraindicated) CT or MRI
Exclusion Criteria:
- Previous or concurrent cancer except
- cervical carcinoma in situ
- treated basal-cell or squamous cell skin carcinoma
- any cancer curatively treated > 3 years before randomization
- curatively treated incidental prostate cancer (T1/T2a)
- Ongoing or previous treatment with anti-FGFR directed therapies (e.g. receptor
tyrosine kinase inhibitors including rogaratinib or FGFR-specific antibodies) or with
taxanes or vinflunine
- More than two prior lines of systemic anti-cancer therapy for urothelial carcinoma
given for advanced unresectable/ metastatic disease
- Ongoing or previous anti-cancer treatment within 4 weeks before randomization.
- Unresolved toxicity higher than National Cancer Institute's Common Terminology
Criteria for Adverse Events, version 4.03 (CTCAE v.4.03) Grade 1 attributed to any
prior therapy/ procedure excluding alopecia, anemia and/ or hypothyroidism
- History or current condition of an uncontrolled cardiovascular disease including any
of the following conditions:
- Congestive heart failure (CHF) NYHA (New York Heart Association) > Class 2
- Unstable angina (symptoms of angina at rest) or new-onset angina (within last 3
months before randomization)
- Myocardial infarction (MI) within past 6 months before randomization
- Unstable cardiac arrhythmias requiring anti-arrhythmic therapy. Patients with
arrhythmia under control with anti-arrhythmic therapy such as beta-blockers or
digoxin are eligible.
- Arterial or venous thrombotic events or embolic events such as cerebrovascular
accident (including transient ischemic attacks), deep vein thrombosis or pulmonary
embolism within 3 months before randomization
- Current evidence of endocrine alteration of calcium phosphate homeostasis (e.g.
parathyroid disorder, history of parathyroidectomy, tumor lysis, tumoral calcinosis,
paraneoplastic hypercalcemia)
- Current diagnosis of any retinal detachment, retinal pigment epithelial detachment
(RPED), serous retinopathy or retinal vein occlusion
- Any hemorrhage / bleeding event ≥ CTCAE v.4.03 Grade 3 within 4 weeks before
randomization
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Objective response rate (ORR) |
Time Frame: | Up to 45 months |
Safety Issue: | |
Description: | Defined as the percentage of patients with complete response (CR) or partial response (PR). Patients for whom overall best response is not CR or PR, as well as patients without any post-baseline tumor assessment will be considered non-responders. |
Secondary Outcome Measures
Measure: | Progression-free survival (PFS) |
Time Frame: | Up to 45 months |
Safety Issue: | |
Description: | Defined as the time (days) from randomization to date of first observed disease progression (radiological or clinical assessment) or death due to any cause, if death occurs before progression is documented. For patients without documented radiological or clinical progression or death at the time of analysis, PFS will be censored at the last actual visit date of tumor evaluation. |
Measure: | Disease-control rate (DCR) |
Time Frame: | Up to 45 months |
Safety Issue: | |
Description: | Defined as the percentage of patients, whose overall best response was not progressive disease [PD] (i.e. CR, PR, Stable Disease [SD] or Non CR/Non PD). Tumor assessments with SD as response, that is performed prematurely after randomization of the patient (i.e. substantially earlier than the first planned radiological tumor assessment at 6 weeks), will not be taken into account. |
Measure: | Duration of response (DOR) |
Time Frame: | Up to 45 months |
Safety Issue: | |
Description: | Defined as the time from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented). DOR will be defined for responders only, i.e. patients with a CR or PR. |
Measure: | Incidence of Adverse Events as a measure of safety and tolerability |
Time Frame: | Up to 45 months |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 2/Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Bayer |
Trial Keywords
Last Updated
November 30, 2020